Cancer immunotherapy developer CEL-SCI's Q3 net loss unchanged
Cancer immunotherapy developer CEL-SCI's Q3 net loss unchanged
Overview
US cancer immunotherapy developer's fiscal Q3 net loss was unchanged from prior year
Basic and diluted net loss per share narrowed to $0.47 from $1.36 a year ago
Company advanced Multikine with new Saudi Arabia partnership and global registration study
Outlook
CEL-SCI set to begin global confirmatory registration study for Multikine in head and neck cancer
Company pursuing Breakthrough Medicine Designation in Saudi Arabia for potential near-term Multikine availability
Early tumor response data from the registration study may be used to seek accelerated U.S. approval
Result Drivers
BIOMARKER STRATEGY - Co said peer-reviewed study identified biomarkers for selecting patients most likely to benefit from Multikine, forming basis for upcoming global registration study
SAUDI ARABIA PARTNERSHIP - Co signed partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia, including pursuit of Breakthrough Designation
CAPITAL RAISE - Co raised $9.7 mln in gross proceeds during the quarter
Company press release: ID:nBw6qkP4sa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $0.47 |
|
Q2 Net Loss |
| $5.7 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CEL-SCI Corp is $10.00, about 549.4% above its August 14 closing price of $1.54
Reuters Recommended Reads
Aug 14 - Cancer diagnostics firm Precipio's Q2 revenue rises, adjusted EBITDA turns positive
Aug 14 - Enveric Biosciences Q2 net loss widens
Aug 14 - Inflammation drug developer HCW Biologics' Q2 net loss widens
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)